United Therapeutics (UTHR) Q2 2026 earnings review
Core Revenue Growth Reverses as Competition Finally Bites
United Therapeutics delivered a mixed Q2 2026. While aggressive share repurchases drove a 13% YoY increase in EPS to $7.27, the underlying business is contracting. Total revenue fell 2% YoY, reversing a multi-year streak of double-digit growth. Management officially conceded that competitive therapies negatively impacted key franchises (Tyvaso DPI, Nebulized Tyvaso, and Remodulin). The entire Tyvaso franchise shrank 4% YoY. The investment thesis now hinges on bridging the gap between current commercial decay and the anticipated 2027 approvals of Ralinepag and Tyvaso for IPF.
🐂 Bull Case
The company submitted NDAs for two major products: ralinepag tablets in PAH and Nebulized Tyvaso in IPF. Management expects these to be multi-billion-dollar drivers with potential approvals in 2027.
UTHR repurchased 2.76 million shares via Accelerated Share Repurchase (ASR) agreements, shielding EPS from top-line weakness. $500 million remains on the current authorization.
🐻 Bear Case
After quarters of dismissing competitor threats, the company explicitly blamed 'competitive therapies' for dragging down Tyvaso DPI, Nebulized Tyvaso, and Remodulin sales.
Total Tyvaso sales reversed from double-digit growth a year ago to a 4% decline. DPI growth decelerated to just 4%, failing to offset an 18% collapse in nebulized sales.
⚖️ Verdict: 🔴
Bearish. Financial engineering and pipeline hype cannot mask the fact that the core commercial engine is stalling. Acknowledging competitive impact is a major narrative shift that warrants caution.
Key Themes
The Competitive Reality Check
Data Contradiction: Throughout FY2025, management aggressively defended the Tyvaso franchise against Liquidia's Yutrepia, repeatedly claiming 'no material impact.' In Q2 2026, the narrative abruptly changed. The SEC release explicitly states that 'the availability of competitive therapies negatively impacted sales of Nebulized Tyvaso, Tyvaso DPI, and Remodulin.' This marks a severe credibility hit regarding management's prior near-term visibility.
Tyvaso Franchise Growth Reversing
The transition from Nebulized Tyvaso to Tyvaso DPI is no longer yielding net franchise growth. Total Tyvaso sales dropped 4% YoY to $452.6 million. DPI sales grew just 4% YoY (decelerating heavily from 22% in Q2 2025), which was not enough to counter the $28.4 million (-18%) drop in Nebulized Tyvaso.
Recurring Inventory Planning Misses
For the second consecutive quarter, UTHR took an inventory reserve expense related to a Tyvaso DPI commercial supply agreement. Following a $26.8 million hit in Q1, Q2 saw an additional $7.5 million charge. This suggests that actual market demand is consistently falling short of internal supply forecasts.
Late-Stage Pipeline Advancements
The company has fully submitted its NDAs for ralinepag tablets (PAH) and Nebulized Tyvaso (IPF). Furthermore, an IND for a ralinepag dry powder inhaler (DPI) and an NDA for a treprostinil soft mist inhaler (SMI) are targeted for later this year. These form the bridge to the 2027 revenue goals.
EPS Buoyed by ASR Executions
Despite a revenue decline, diluted EPS grew 13% YoY, heavily supported by the execution of a $1.5 billion ASR. The diluted share count dropped from 48.3 million in Q2 2025 to 45.8 million in Q2 2026, artificially tightening the bottom line.
Organ Manufacturing Approaching Commercial Reality
Beyond pharmaceuticals, UTHR is advancing its xeno-organ pipeline. Management announced plans to launch two xeno-organ production facilities in Minnesota and Texas later this year, shifting this from a theoretical R&D project toward eventual commercial infrastructure.
Other KPIs
Reversing. Down 4% YoY. This is the first notable YoY contraction for the franchise in recent history, driven by an 18% decline in nebulized formats and a severe deceleration in DPI growth (+4%).
Accelerating. Up 9% YoY. Increased spend is primarily driven by cardiopulmonary treatment projects and fair value adjustments to contingent considerations for manufactured organ projects.
Accelerating significantly against declining revenue. Up 14% YoY, heavily impacted by a $7.5 million inventory reserve for Tyvaso DPI. This structural gross margin pressure needs to be monitored.
Guidance
Management expects potential approvals for Nebulized Tyvaso in IPF and ralinepag tablets in PAH by 'next year' (2027). The company provided no short-term numerical revenue or earnings guidance.
Key Questions
Quantifying Competitive Impact
You explicitly noted that competitive therapies negatively impacted Tyvaso and Remodulin sales this quarter. Can you quantify how much of the $28 million decline in Nebulized Tyvaso was lost to competitors versus cannibalized by Tyvaso DPI?
Recurring Inventory Reserves
We've now seen consecutive quarters with multi-million dollar inventory reserve charges for Tyvaso DPI ($26.8M in Q1, $7.5M in Q2). Are these charges now fully behind us, or do your current supply agreements require further renegotiation based on the new demand baseline?
Bridge to 2027
With the core commercial engine shrinking 2% YoY, how do you expect to fund your expanding R&D operations and maintain operating margins between now and the potential 2027 pipeline approvals?